insights_auto
Prečo akcie HROW klesli 3,80%?
Preskúmať podrobnejšiechevron_right
HROW:NASDAQ
Harrow Inc
29,36 USD
arrow_downward
-3,80%(-1,16) 1 d.
29,61 USD
arrow_upward
+0,85% (+0,25)bedtimePo uzavretí
Zavreté: 9. 10., 16:00:01 GMT-4 · USD
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre HROW…
Otvoriť
30,73 USD
Vysoká
30,90 USD
Nízka
27,00 USD
Trh. kap.
1,10 mld.
Priem. obj.
550,16 tis.
Objem
1,35 mil.
Max. za 52 týž.
54,85 USD
Min. za 52 týž.
27,00 USD
Výnosy na akciu
-1,00 USD
Beta
0,19
Akcie v obehu
37,49 mil.
Počet zamestnancov
373
Otvoriť
30,73 USD
Vysoká
30,90 USD
Nízka
27,00 USD
Trh. kap.
1,10 mld.
Priem. obj.
550,16 tis.
Objem
1,35 mil.
Max. za 52 týž.
54,85 USD
Min. za 52 týž.
27,00 USD
Výnosy na akciu
-1,00 USD
Beta
0,19
Akcie v obehu
37,49 mil.
Počet zamestnancov
373
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
Investing.com
·
pred 1 dňom
Harrow stock hits 52-week low at 28.51 USD
Zacks
·
pred 1 dňom
Do Options Traders Know Something About Harrow Stock We Don't?
Simply Wall Street
·
pred 2 dňami
Clinical Data Showcase Could Be A Game Changer For Harrow (HROW)
Yahoo Finance Singapore
·
pred 3 dňami
Is Harrow (HROW) Undervalued On Growing Conference Buzz Around Its Ophthalmic Pipeline?
Profil
Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee.
Since 2014, Harrow has started six healthcare businesses, including ImprimisRx, an ophthalmic-focused pharmaceutical company. In 2017, Harrow started and funded Eton Pharmaceuticals with a $20 million Series A financing, and Eton is now a publicly traded company. In 2017, Harrow started Surface Pharmaceuticals, hiring Dr. Kamran Hosseini to be its chief executive officer. Surface was funded with a $20 million Series A financing with Flying L Partners leading the round. In 2018, Harrow started Melt Pharmaceuticals and announced an $11 million Series A financing.
In 2019, Harrow hired founder and former CEO of Doxy.me, Drew Livingston, as its chief innovation officer. Livingston is the senior executive of Harrow's Visionology.com telemedicine subsidiary. Wikipedia
Informácie o subjekte Harrow Inc
Generálny riaditeľMark L. Baum Esq.
Zamestnanci373
Dátum založenia2012
Hlavné sídloNashville, Tennessee, Spojené štáty americké
Odvetvie-
Webharrow.com